skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

The 2021 Scrip Award winners by category:

  • MSD's Innovation Award – Sponsored by MSD: Moderna’s mRNA vaccine technology
  • China Biopharma Leadership Award: BeiGene China
  • Financing Deal of the Year: Amphista Therapeutics’ $53m series B
  • Clinical Advance of the Year – Sponsored by Parexel: Takeda Pharmaceutical Company's Phase III SOLSTICE trial of maribavir in transplant recipients with CMV infection
  • Business Development Team of the Year: Evox Therapeutics
  • Best Partnership Alliance: BenevolentAI and AstraZeneca for AI and machine learning to discover potential new treatments for chronic kidney disease and idiopathic pulmonary fibrosis
  • Best Contract Research Organization - Specialist Providers: MMS Holdings
  • Best Contract Research Organization - Full Service Providers – Sponsored by Clario, an ERT Company: ICON
  • Licensing Deal of the Year: Roche and Regeneron for the development, manufacture and commercialization of REGN-COV2 for COVID-19
  • Community Partnership of the Year: Accord Healthcare and International Health Partners
  • Clinical Advance of the Year - COVID-19 Pandemic Special Recognition Award – Sponsored by Parexel: CluePoints, BioNTech and Pfizer’s Phase I/II/III study of SARS-COV-2 RNA vaccine BNT162b2 (Comirnaty) and: Moderna’s Phase III COVE study of mRNA-1273 for COVID-19 prevention
  • Best New Drug - COVID-19 Pandemic Special Recognition Award: AstraZeneca’s Vaxzevria COVID-19 Vaccine, and: BioNTech and Pfizer’s Comirnaty (BNT162b2), and: Johnson & Johnson’s single-dose COVID-19 Vaccine, and: Moderna’s COVID-19 Vaccine (mRNA1273)
  • Executive of the Year - Development-stage or companies with a market cap of <$5bn: Jingwu Zang, founder, chairman and director of I-Mab
  • Executive of the Year - Commercial-stage and companies with a market cap of >$5bn: John V Oyler, co-founder, chairman and chief executive officer of BeiGene
  • WuXi AppTec's Biotech Company of the Year Award – Sponsored by WuXi AppTec: ADC Therapeutics
  • Best New Drug Award - non COVID-19: GlaxoSmithKline’s Blenrep (belantamab mafodotin) for multiple myeloma
  • Pharma Company of the Year – Sponsored by IQVIA: Moderna
  • Scrip's Lifetime Achievement Award – Sponsored by ICON: Dame Kate Bingham and Clive Dix

 

London, 3 December 2021: Informa Pharma Intelligence announced the winners of the 17th edition of the Scrip Awards last night, hosted live in London. The Scrip Awards honours the outstanding accomplishments of those improving human healthcare worldwide through their work in the pharmaceutical, biotech, and allied industries. The winners encompassed the Scrip Awards’ 18 categories, spanning a wide range of industry activities.

MSD's Innovation Award – Sponsored by MSD was won by Moderna’s mRNA vaccine technology, used in the sequence for mRNA-1273, one of the first vaccines developed to combat the global COVID-19 pandemic. Judges said, “This is truly a game changer in vaccine technology.”

BeiGene China took home the China Biopharma Leadership Award for excellence in advancing this maturing sector. Judges called BeiGene China’s 2021,“an outstanding year in the development of this rapidly growing business.”

Financing Deal of the Year was awarded to Amphista Therapeutics’ $53m series B fundraising.  “This was an outstanding year for Amphista with a heavily oversubscribed series B fundraising that achieved a 50% uplift of the original target coming less than a year after its series A, attracting significant new European and Corporate VCs,” judges said.

Takeda Pharmaceutical Company's Phase III SOLSTICE trial of maribavir in transplant recipients with CMV infection was described by judges as, “a game changer for transplant patients” and was named the winner of the Clinical Advance of the Year, sponsored by Parexel.

The business development team at Evox Therapeutics captured the Business Development Team of the Year award for their deal with Eli Lilly, comprised of a significant upfront and worth up to $1.2bn for potential treatments for neurological disorders. Judges praised them for their “systematic approach to capturing a big opportunity.”

Best Partnership Alliance went to BenevolentAI and AstraZeneca for “an excellent example of an alliance for the development of targeted therapies using the interrogation of big data to search for new targets,” according to the judges.

MMS Holdings won Best Contract Research Organization - Specialist Providers. Their achievements include completing over 50 submissions for drug approval during the last five years, gaining an FDA fast-track designation for a non-opioid painkiller, and offering a seven-figure award toward a COVID-19 vaccine.

Best Contract Research Organization – Full-Service Providers, sponsored by Clario, an ERT Company, was awarded to ICON for their work in advancing clinical research across product lifecycles, including providing clinical trial services to the Pfizer and BioNTech investigational COVID-19 vaccine programme.

Roche and Regeneron’s development, manufacture and commercialization of REGN-COV2 for COVID-19 yielded a win for Licensing Deal of the Year, which the judges called “a truly unique partnership to address a global need during challenging times.”

Community Partnership of the Year went to Accord Healthcare and International Health Partners for their efforts to provide medicines to hard-to-reach, vulnerable and disaster-hit communities, including during the COVID-19 pandemic.

CluePoints, BioNTech, and Pfizer’s Phase I/II/III study of SARS-COV-2 RNA vaccine BNT162b2 (Comirnaty) as well as Moderna’s Phase III COVE study of mRNA-1273 for COVID-19 prevention won the Clinical Advance of the Year – COVID-19 Pandemic Special Recognition Award, Sponsored by Parexel. Judges recognized the challenges and achievements for the two mRNA-based COVID-19 vaccines in taking novel technology to market with unprescedented speed.

AstraZeneca’s Vaxzevria COVID-19 Vaccine, BioNTech and Pfizer’s Comirnaty (BNT162b2), Johnson & Johnson’s single-dose COVID-19 Vaccine, and Moderna’s COVID-19 Vaccine (mRNA1273) were all recognized for their immeasurable impact on fighting the spread of the deadly virus, jointly sharing honours for the Best New Drug – COVID-19 Pandemic Special Recognition Award. BioNTech and Pfizer’s Comirnaty (BNT162b2) became the first COVID-19 vaccine to receive regulatory approval, just 266 days after the pandemic was declared. Moderna was the first company to launch a SARS-CoV-2 vaccine trial in humans with Spikevax (mRNA1273), while AstraZeneca’s Vaxzevria (ChAdOx1-SARS-COV-2) was developed in partnership with Oxford University and has been used in over 165 countries. Finally, Johnson & Johnson’s single-dose COVID-19 vaccine was brought to the public on a not-for-profit basis for emergency pandemic use following its first emergency use approvals, including in the US, in February 2021.

Executive of the Year - Development-stage or companies with a market cap of <$5bn was awarded to Jingwu Zang, Founder, Chairman, and Director of I-Mab since 2016. Dr. Zang led the company into a groundbreaking $2.94 billion global partnership with AbbVie on the differentiated anti-CD47 monoclonal antibody, lemzoparlimab, the largest biotech out-licensing deal from China. Judges called I-Mab, “truly a new-age biopharma company.”

John V Oyler, Co-Founder, Chairman and Chief Executive Officer of BeiGene was named Executive of the Year - Commercial-stage and companies with a market cap of >$5bn. During the past year alone, the company’s market capitalization multiplied to $33B+ while expanding its diverse pipeline to 40+ commercial or clinical stage assets while developing a new cancer therapy launch. Judges praised Oyler for, finding solutions for human health.”

WuXi AppTec's Biotech Company of the Year Award – Sponsored by WuXi AppTec was given to ADC Therapeutics, whose achievements the past year included the accelerated FDA approval of its lead antibody drug conjugate Zynlonta, the first and only CD19-targeted ADC for the treatment of r/r DLBCL, filling a substantial unmet need in heavily pretreated patients with difficult to treat disease.

GlaxoSmithKline’s Blenrep (belantamab mafodotin) for multiple myeloma secured the Best New Drug Award – non-COVID-19, the first antibody drug conjugate (ADC) approved for multiple myeloma and the first anti-B-cell maturation antigen (BCMA) therapy approved worldwide. The judges described Blenrep as a “major advance” in multiple myeloma with “very significant efficacy.”

Pharma Company of the Year – Sponsored by IQVIA was awarded to Moderna, for their pivotal role in the worldwide response to the COVID-19 pandemic, which transformed the organisation from a clinical-stage company into a multibillion-dollar concern.

Dame Kate Bingham and Clive Dix shared the honours for Scrip’s Lifetime Achievement Award – Sponsored by ICON. Both Bingham and Dix acted as Chair of the UK Vaccine Taskforce, and each has been an important figure in the UK life sciences throughout their distinguished careers, making significant contributions in the areas of venture capital and R&D.

Alex Shimmings, Executive Editor, Commercial/R&D at Informa Pharma Intelligence, said, “Congratulations to all of this year’s winners and thank you to our headline sponsor ICON and all our other sponsors who have contributed to this fantastic event.”

“Despite the challenges of the past 18+ months, the pharma industry has shown both incredible resilience and dedication, which was clearly noticeable in the extremely high quality of entries,” she continued.

“An extended thank you to our jury for their time, all the nominees for their achievements, and, of course, to this year’s winners! We look forward to seeing you all again next year!” Shimmings concluded.

 

For more information on the Scrip Pharma Awards please visit: pharmaintelligence.informa.com/ScripAwards

 

About Informa Pharma Intelligence

Informa Pharma intelligence powers a full suite of analysis products — Scrip, Datamonitor Healthcare, Citeline, Medtrack, Sitetrove, Pharmaprojects, Biomedtracker, Meddevicetracker, Pink Sheet, and In Vivo – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information, visit pharmaintelligence.informa.com.

About Informa PLC

Informa operates at the heart of the Knowledge and Information Economy. It is a leading global business intelligence, academic publishing, knowledge, and events businesses. With more than 6,500 employees globally, it has a presence in all major geographies, including North America, South America, Asia, Europe, the Middle East and Africa.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: